Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMR vs CRP Guidance for Anakinra in Recurrent Pericarditis
NCT06071156Recruiting
- Sponsor
- Azienda Ospedaliero-Universitaria delle Marche
- Start
- Jan 2018
- Primary completion
- May 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of anakinra in recurrent pericarditis (2 arms), sponsored by Azienda Ospedaliero-Universitaria delle Marche. Primary endpoint: Recurrences of pericarditis at 6 months. Started Jan 2018; status: recruiting.
02
Drugs
anakinra
03
Conditions
recurrent pericarditis
Beyond the preview
Go deeper on NCT06071156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06071156.